Popular Articles

ITC results bode well for FMCG firms
Fast moving consumer goods (FMCG) companies are likely to register a modest growth for the July-September 2009 quarter on the back of rising consumer demand which is expected to considerably reduce the impact of a disappointing monsoon on sales. Traditionally, summer and winter months make up 30-40 per cent of any FMCG company’s overall sales.

Suryakirans to enthrall Dasara crowds
Mysoreans will have the opportunity of witnessing for the first time thrilling aerobatic demonstration by the renowned Suryakiran team of the Indian Air Force (IAF) during this Dasara.

News of the day

S Madhavan: We're a long way from being ready for the GST
From setting the rates, to the constitutional changes required and the training needed, it is unlikely we will be able to implement it by April 2010, says S Madhavan.
Home Business

Analysts' corner

GAIL Reco price: Rs 402 Sensex pares gains; Hindalco up 4% Loan prepayment does not violate competition laws:Banks SRK stands by his IPL remarks, says India a welcoming place Obama proposes substantial jump in aid to Pak Oil rises on bullish US manufacturing data Commencement of KG-D6 gas, concomitant with the Rs 30,000 crore network expansion plan encompassing the addition of 7,000 km of gas pipelines, should result in a 37 per cent CAGR volume growth for GAIL over FY09-FY12. Aided by volume expansion, EBITDA of the transmission business is likely to exhibit 20 per cent CAGR over this period. However, the 3 per cent CAGR of the petrochemical/LPG division is expected to dampen overall performance, given a weak environment. The brokerage models a flat HVJ tariff based on the assumption of expansion-related capex of Rs 11,000 crore. The brokerage says that its earnings estimates for GAIL would decline by 4 per cent for a 10 per cent reduction in HVJ tariffs. Their subsidy model factors in two-thirds of the upstream share of auto-fuel under-recovery for 2009-10 and 2010-11, a sharing scenario which favour upstream companies. GAIL is currently trading at 17 times one-year forward PE, almost double of its 5-year historical average. While this valuation premium factors in expectation of robust gas volume growth outlook and higher existing tariffs, earnings growth of 4 per cent CAGR over FY09-FY12 could make it difficult to sustain. The petrochemical/LHC business outlook, too, continues to be grim. The brokerage has initiated a ‘Sell’ rating with a target price of Rs 370. [----------] BAJAJ HINDUSTHAN Reco price: Rs 207 Current market price: Rs 212.20 Target price: Rs 234 Upside: 10.3% Brokerage: Religare Hichens, Harrison For year ending September 2009, Bajaj Hindusthan’s sugar volumes dropped 27 per cent year-on-year to 6.7 MT, primarily due to lower cane crushing and a depleted sugar inventory. Nevertheless, a steep increase in sugar realisations aided a 1.7 per cent year-on-year growth in sugar revenues to Rs 1,870 crore for the full year. The company crushed 5.4 MT of cane during the year, as against 10 MT last year. On account of such paucity of raw material (molasses and bagasse), both alcohol and co-gen (power) segments recorded a sharp drop in revenues and operating profits for the year. Bajaj Hindusthan recorded an EBITDA margin of 22.5 per cent in September 2009 quarter as against 7.3 per cent in the quarter of last year. It recorded a currency swap gain of around Rs 70 crore, leading to a more than five-fold rise in its other income during the quarter. This, along with lower interest outgo, enabled the company to make a net profit of Rs 69 crore in September 2009 quarter as against a net loss of Rs 87.5 crore in year ago quarter. Despite concerns on relatively higher cane procurement cost of around Rs 205-210 per quintal, buoyant sugar realisations of Rs 33-33.5 per kg have surprised the brokerage positively. Maintain Buy.[----------] INFOSYS TECHNOLOGIES Reco price: Rs 2,545 Current market price: Rs 2,526.50 Target price: Rs 3,020 Upside:19.5% Brokerage: Angel Broking New engagement models (NEM) are expected to be the key growth drivers for Infosys’ overall business, going forward. Infosys currently has 84 clients in NEM model with deal size of around $165 million and is looking at NEM opportunities, which would be greater than $500 million to be executed, going forward. The company"s efforts on the non-linear front are expected to contribute around 33 per cent to its overall revenues, up from the current 5 per cent. The Consulting and Package Implementation services is also expected to register robust growth, contributing around 30 per cent to the company"s revenues, with the balance expected to be contributed by the core ADM services in the next five years time frame. As per the company, interactions with its clientele indicates that IT budgets for CY10 are expected to be flat or marginally lower as there still exists some uncertainty with respect to economic revival. However, Infosys’ increasing focus on non-linear initiatives along with its strategy to focus on newer geographies and services are positive. At Rs 2,545, Infosys trades at 21.7 times its estimated 2010-11 EPS, leaving room for further upside. Maintain buy.[----------] JUBILANT ORGANOSYS Reco price: Rs 339 Current market price: Rs 338.15 Target price: NA Brokerage: Edelweiss Securities Healthy order book and new contracts in Jubilant Organosys’ Pharma and Life Sciences Products and Services (PLSPS) business is expected to deliver 15 per cent overall revenue growth in 2009-10, after a healthy organic growth of 31 per cent in PLSPS in 2008-09. In FY10, Jubilant revised upwards its EBITDA guidance to 45 per cent year-on-year growth from 30 per cent earlier, based primarily on recent wins in the contract manufacturing operations that offer better margins. Debt repayment that includes FCCBs, amounting to Rs 1,800 crore over FY10-12 is challenging. Projected cash flows are likely to cover almost 70-80 per cent of these repayments, with de-leveraging and likely asset sale of non-core assets bridging the gap. Post above repayments, Jubilant’s debt-equity will reduce substantially to around 1.1 from current 2.2 levels, accordingly. From a peak of 17-18 times one-year forward earnings in 2007, Jubilant suffered a sharp valuation de-rating in late 2008, with market concerns on the company’s ability to finance its FCCBs. Current earnings trajectory, strength of PLSPS and cash flows suggest that concerns may be overplayed. The stock is currently trading at 11 times and 8 times its estimated 2010-11 and 2011-12 consensus earnings, respectively a sharp discount to its historical valuations.[----------] NESTLE INDIA Reco price: Rs 2,568 Current market price: Rs 2,525.55 Target price: Rs 2,915 Upside:15.4% Brokerage: India Infoline With the healthy growth in the domestic business and revival in exports, expect Nestle to witness 17.7 per cent CAGR in revenues and 24.6 per cent in profit over CY09-11. Milk products and prepared dishes segments will be the key growth drivers for the company. The introduction of SKUs at low price points has helped to widen the consumer base and increase penetration of its brands. The improvement in exports from CY10 onwards is expected to fuel beverage sales that declined in the first nine months of CY09. The growth in the chocolates’ segment, that reported a muted volume growth due to sharp price hikes, is also expected to be back on track during CY10. The strong pricing power and robust brand portfolio would help Nestle maintain operating margins despite firm raw material prices. With the increasing production from the Pant Nagar plant, Nestle would be able to save heavily on excise and tax front. Given the strong growth potential in the domestic market, the brokerage has revised its earnings estimates upwards by 3 per cent for CY09 and around 4 per cent for CY10. At Rs 2,568, the stock is trading at 29.4 times its estimated CY10 EPS of Rs 88.3 and 24 times estimated CY11 EPS of Rs 107.2. Maintain buy. Current market prices as on December 18


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):